1cBio is an emerging biotechnology company which strives to identify white spaces in cancer therapies and develop molecules that can serve as precision medicines. The company's programs are geared to treat the disease and preemptively counter mechanisms for acquired or intrinsic resistance. Core expertise in medicinal chemistry and translational sciences along with thought partners in clinical and basic sciences guides 1cBio's innovation. 1cBio's second lead program is OC-3, a selective-PARP1 inhibitor with the potential to be best-in-class for HR-deficient and HR-proficient tumors when combined with approved targeted therapies.
